Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DCPH NASDAQ:IBRX NASDAQ:NUVL NYSE:QGEN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDCPHDeciphera Pharmaceuticals$25.59$25.59$9.90▼$25.61$2.21B0.191.29 million shsN/AIBRXImmunityBio$7.36-2.2%$7.69$1.95▼$12.43$7.70B0.0329.00 million shs11.93 million shsNUVLNuvalent$99.57-9.8%$103.03$71.13▼$113.01$7.87B1.15576,899 shs1.83 million shsQGENQiagen$36.43-0.4%$37.69$32.53▼$57.81$7.50B0.662.30 million shs817,363 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDCPHDeciphera Pharmaceuticals0.00%0.00%0.00%0.00%0.00%IBRXImmunityBio0.00%+4.16%+5.92%-27.97%+181.65%NUVLNuvalent0.00%+8.10%+10.08%+8.98%+49.93%QGENQiagen0.00%+3.94%+5.90%-25.01%-22.92%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDCPHDeciphera Pharmaceuticals$25.59$25.59$9.90▼$25.61$2.21B0.191.29 million shsN/AIBRXImmunityBio$7.36-2.2%$7.69$1.95▼$12.43$7.70B0.0329.00 million shs11.93 million shsNUVLNuvalent$99.57-9.8%$103.03$71.13▼$113.01$7.87B1.15576,899 shs1.83 million shsQGENQiagen$36.43-0.4%$37.69$32.53▼$57.81$7.50B0.662.30 million shs817,363 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDCPHDeciphera Pharmaceuticals0.00%0.00%0.00%0.00%0.00%IBRXImmunityBio0.00%+4.16%+5.92%-27.97%+181.65%NUVLNuvalent0.00%+8.10%+10.08%+8.98%+49.93%QGENQiagen0.00%+3.94%+5.90%-25.01%-22.92%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDCPHDeciphera Pharmaceuticals 0.00N/AN/AN/AIBRXImmunityBio 2.71Moderate Buy$14.2093.07% UpsideNUVLNuvalent 2.94Moderate Buy$140.2940.89% UpsideQGENQiagen 2.42Hold$44.9823.46% UpsideCurrent Analyst Ratings BreakdownLatest DCPH, NUVL, IBRX, and QGEN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/29/2026QGENQiagen Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D+)5/28/2026NUVLNuvalent WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$125.005/21/2026NUVLNuvalent Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$189.005/21/2026NUVLNuvalent Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$189.005/21/2026IBRXImmunityBio BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$12.005/21/2026NUVLNuvalent Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy5/20/2026IBRXImmunityBio HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$15.005/18/2026QGENQiagen Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetHold$50.00 ➝ $36.005/18/2026QGENQiagen CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold5/12/2026QGENQiagen Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C) ➝ Hold (C-)5/8/2026IBRXImmunityBio BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$12.00(Data available from 6/1/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDCPHDeciphera Pharmaceuticals$174.91M12.65N/AN/A$4.38 per share5.84IBRXImmunityBio$113.29M68.00N/AN/A($0.51) per share-14.42NUVLNuvalentN/AN/AN/AN/A$15.95 per shareN/AQGENQiagen$2.09B3.59$3.39 per share10.75$17.89 per share2.04Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDCPHDeciphera Pharmaceuticals-$194.94M-$2.21N/AN/AN/A-108.86%-52.42%-40.05%N/AIBRXImmunityBio-$351.40M-$0.85N/AN/AN/A-606.15%N/A-59.53%8/4/2026 (Estimated)NUVLNuvalent-$425.38M-$6.06N/AN/AN/AN/A-40.11%-35.43%8/6/2026 (Estimated)QGENQiagen$424.88M$1.9119.0113.803.6419.16%14.40%8.40%8/4/2026 (Estimated)Latest DCPH, NUVL, IBRX, and QGEN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026IBRXImmunityBio-$0.08-$0.62-$0.54-$0.62$43.07 million$44.21 million5/7/2026Q1 2026NUVLNuvalent-$1.35-$1.39-$0.04-$1.39$0.49 millionN/A5/7/2026Q1 2026QGENQiagen$0.54$0.54N/A$0.33$496.15 million$492.32 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthDCPHDeciphera PharmaceuticalsN/AN/AN/AN/AN/AIBRXImmunityBioN/AN/AN/AN/AN/ANUVLNuvalentN/AN/AN/AN/AN/AQGENQiagen$0.260.71%N/A13.61%N/ALatest DCPH, NUVL, IBRX, and QGEN DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/11/2026QGENQiagenannual$0.351.04%7/7/20267/7/20267/14/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDCPHDeciphera PharmaceuticalsN/A4.193.94IBRXImmunityBioN/A6.676.66NUVLNuvalentN/A16.1416.14QGENQiagen0.493.212.57Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDCPHDeciphera Pharmaceuticals70.96%IBRXImmunityBio8.58%NUVLNuvalent97.26%QGENQiagen70.00%Insider OwnershipCompanyInsider OwnershipDCPHDeciphera Pharmaceuticals4.67%IBRXImmunityBio69.48%NUVLNuvalent5.02%QGENQiagen9.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDCPHDeciphera Pharmaceuticals30086.48 million82.44 millionNo DataIBRXImmunityBio5901.05 billion319.65 millionOptionableNUVLNuvalent4079.00 million75.03 millionOptionableQGENQiagen5,654206.07 million187.53 millionOptionableDCPH, NUVL, IBRX, and QGEN HeadlinesRecent News About These CompaniesLegal & General Group Plc Sells 40,221 Shares of Qiagen N.V. $QGENMay 30 at 5:17 AM | marketbeat.comIs QGEN Stock a Hold After the 2026 Outlook Cut and Q1 Miss?May 29 at 10:20 AM | zacks.comQIAGEN Supports Infectious Disease Research and Surveillance Efforts for Bundibugyo Ebolavirus OutbreakMay 28, 2026 | businesswire.comQIAGEN Business Breakdown and Growth Drivers for 2026May 28, 2026 | zacks.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Qiagen N.V. - QGENMay 28, 2026 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Qiagen N.V. - QGENMay 26, 2026 | globenewswire.comQiagen N.V. (NYSE:QGEN) Given Average Recommendation of "Moderate Buy" by BrokeragesMay 24, 2026 | americanbankingnews.comQGEN INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Qiagen N.V.May 21, 2026 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Qiagen N.V. - QGENMay 21, 2026 | prnewswire.comQIAGEN Stock Up on the Launch of AI-Powered Workflow Agent PlatformMay 21, 2026 | zacks.comQIAGEN launches QIA Agent, connecting AI-driven scientific guidance across Sample to Insight workflowsMay 20, 2026 | businesswire.com3 Stocks in Focus That Recently Declared Dividend Hikes Amid High InflationMay 20, 2026 | zacks.comQiagen (QGEN) Securities Fraud Investigation - Levi & KorsinskyMay 20, 2026 | prnewswire.comQGEN INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Qiagen N.V.May 19, 2026 | businesswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Qiagen N.V. - QGENMay 19, 2026 | globenewswire.comQIAGEN to advance AI-driven drug discovery with graph-based AI and curated bioinformatics knowledge with NVIDIAMay 19, 2026 | businesswire.comBarclays Remains a Hold on Qiagen (QGEN)May 18, 2026 | theglobeandmail.comQIAGEN INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Qiagen N.V.May 15, 2026 | globenewswire.comQGEN SHAREHOLDER ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Potential ...May 15, 2026 | caledonianrecord.comCQiagen NV (QGEN) price target decreased by 13.91% to 46.28May 15, 2026 | msn.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Qiagen N.V. - QGENMay 14, 2026 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeDCPH, NUVL, IBRX, and QGEN Company DescriptionsDeciphera Pharmaceuticals NASDAQ:DCPHDeciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.ImmunityBio NASDAQ:IBRX$7.36 -0.17 (-2.19%) As of 02:07 PM Eastern This is a fair market value price provided by Massive. Learn more.ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.Nuvalent NASDAQ:NUVL$99.57 -10.82 (-9.80%) As of 02:07 PM Eastern This is a fair market value price provided by Massive. Learn more.Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.Qiagen NYSE:QGEN$36.43 -0.16 (-0.43%) As of 02:07 PM Eastern This is a fair market value price provided by Massive. Learn more.QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/25 - 05/29 Gap Inc. Cuts Sales Outlook After Q1 Miss, Shares Drop 17% What Exactly Is Agentic AI, and Why Are Some Stocks Blowing Up Because of It? Costco’s Strong Quarter Still Leaves Investors With a Valuation Problem SanDisk's Stock and Short Interest Both at Record Highs —Do the Bears Know Something? MongoDB's AI Advantage Is Starting to Show Up in Results 3 Ways to Play the Data Center Land Grab Alphabet Bets on Hardware With Googlebook and AI Glasses Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
